Table 2.
List of modulators available for shaping mCa2+ signaling as potential therapeutic approach.
| Therapeutic Target | Compound | Side Effects | Cell Permeability | In Vivo Applicability | References |
|---|---|---|---|---|---|
| MCU | anti-miR25 | Not observed | Yes | ND | [86] |
| Ru265 | Not observed | Yes | ND | [231] | |
| DS16570511 | ΔΨm loss and cell death | Yes | No | [232,234,235] | |
| Mitoxantrone | Cardiotoxicity | Yes | Limited | [236,237] | |
| Kaempferol | Not observed | Yes | Yes | [249,250] | |
| SB202190 | Not observed | Yes | ND | [249] | |
| KB-R7943 | Not selective | Yes | ND | [265] | |
| MICU1 | MCU-i4 and MCU-i11 | Not observed | Yes | ND | [267] |
| NCLX | KB-R7943, | Not selective | Yes | ND | [255,262,264] |
| CGP-37157 | Not observed | Yes | ND | [257,259] | |
| SEA0400 | Not observed | Yes | ND | [255,256] | |
| mPTP | Cyclosporin A | Not observed | Yes | ND | [270] |
| 1,3,8-Triazaspiro[4.5]decane derivatives | Not observed | Yes | ND | [274] | |
| SERCA | Thapsigargin | Not selective | Yes | No | [241] |
| Mipsagargin G-202 | Not observed | Yes | Yes | [243] | |
| Resveratrol and piceatannol | Not observed | Yes | Limited bioavailability | [244] | |
| MAMs: BCl2-IP3R3 | BIRD-2 | Not observed | Yes | ND | [238,239] |
Abbreviations: ND, not determined.